| 货号 | 18099-25mg |
| 描述 | Polo-like kinases (Plks) are serine/threonine kinases with key roles in cell cycling.1 GSK461364 is a potent, reversible inhibitor of Plk1 (Ki = 2.2 nM).2 It is less effective against Plk2 and Plk3 (Kis = 860 and 1,000 nM, respectively) and at least 1,000-fold selective for Plk1 over a panel of 48 other kinases.2 GSK461364 dose-dependently halts cell cycling in diverse proliferating cancer cell lines and, at higher doses, triggers apoptosis.2 It appears to be more effective against p53-deficient tumors and is able to cross the blood-brain barrier.3,4 GSK461364 is effective in vivo, inducing tumor growth inhibition or growth delay in xenograft models in mice.1,2 |
| 别名 | GSK461364A; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Schöffski, P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14(6), 559-570 (2009). 2.Gilmartin, A.G.,Bleam, M.R.,Richter, M.C., et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Research 69(17), 6969-6977 (2009). 3.Degenhardt, Y.,Greshock, J.,Laquerre, S., et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Molecular Cancer Therapeutics 9(7), 2079-2089 (2010). 4.Danovi, D.,Folarin, A.,Gogolok, S., et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS One 8(10), 1-13 (2013). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 543.6 |
| 分子式 | C27H28F3N5O2S |
| CAS号 | 929095-18-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |